FY2025 · ended Dec 31, 2025 · Revenue $147.17M, +17.2% YoY · Filed Mar 12, 2026
GRAIL, Inc. (GRAL) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $147.2 million and a net loss of $408.4 million. Free cash flow was -$299.9 million. As of Sep 30, 2026 it held $29.0 million in cash and investments and $85.8 million in total debt.
Revenue (TTM)
$166.60M
+17.5% vs year-ago TTM
Net income (TTM)
$-406.18M
+0.0% vs year-ago TTM
Operating cash flow (TTM)
$-306.24M
+6.8% vs year-ago TTM
Free cash flow (TTM)
$-312.00M
EPS (TTM)
$-9.27
+20.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
41.02M
+21.0% vs prior year
Net cash
$-56.87M
as of Sep 30, 2026
Operating margin
-347.3%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- GRAL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Sunnyvale, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1699031
- Former names
- GRAIL, LLC (until Jun 12, 2024)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $147.2M | $125.6M |
| Operating income | -$562.2M | -$2.2B |
| Net income | -$408.4M | -$2.0B |
| Diluted EPS | -$11.11 | -$63.54 |
| Operating cash flow | -$299.0M | -$577.2M |
| Free cash flow | -$299.9M | -$582.4M |
| Total assets | $2.9B | $3.0B |
| Total liabilities | $344.2M | $479.9M |
| Stockholders' equity | $2.6B | $2.5B |
| Cash and investments | $249.7M | $214.2M |
| Total debt | $54.9M | $68.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Jun 1, 2026 | Jun 1, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 265 GRAIL, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.